Stemedica


email icon Want to stay informed?
Sign up for our email
newsletter here

CURRENT NEWS RELEASES

PRESIDENT OF LEADING SOUTH KOREAN BIOPHARMACEUTICAL COMPANY GREEN CROSS HOLDINGS JOINS STEMEDICA’S BOARD OF DIRECTORS
(Source: April 22; San Diego)

Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors. Green Cross, whose recent investment closed Stemedica’s Series B funding round, is one of the world’s largest vaccine and plasma product manufacturers, and the company’s influence in Asia, China and the United States spans advanced research and development, biotech manufacturing and product development. Dr. Rhee’s addition to Stemedica’s board supports both companies’ shared vision of moving stem-cell technologies from clinical trials into worldwide medical practice.

STEMEDICA APPOINTS NIH CENTER FOR REGENERATIVE MEDICINE FOUNDING DIRECTOR DR. MAHENDRA RAO
TO ITS SCIENTIFIC AND MEDICAL ADVISORY BOARD

Renowned Stem Cell and Regenerative Medicine Authority Will Help Stemedica in Its Plans to Meet the
Global Demand for Stem Cell Technology

(Source: April 8; San Diego)

Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes to its Scientific and Medical Advisory Board prominent stem cell and regenerative medicine expert Dr. Mahendra Rao, M.D., Ph.D. As a Founding Director of the National Institute of Health (NIH) Center for Regenerative Medicine (CRM), he has built the Center into a world-class organization recognized for its excellence in the clinical translation of stem cell technology, and his expertise will help Stemedica shape its strategy to meet global demand for its stem cell technology.

STEMEDICA ANNOUNCES INTERNATIONAL EDUCATIONAL COLLABORATION WITH SMART LIVING
(Source: March 26; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies and Smart Living, a subsidiary of Smart Global, a $2 billion (USD) globally diversified conglomerate, are pleased to announce an international educational collaboration.

STEMEDICA ISSUED U.S. PATENT METHOD FOR IDENTIFYING NEURIPOTENT CELLS
(Source: Feburary 18; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the Company has been issued Patent No. US 8,642,286 B2 entitled, Methods for Identifying Neuripotent Cells by the United States Patent and Trademark Office.

Stemedica Subsidiary News: NEW PHASE IIA TRIAL IN THE UNITED STATES AND PHASE III TRIAL IN KAZAKHSTAN STUDY THE USE OF CARDIOCELL’S ITMSC THERAPY FOR TREATING ACUTE MYOCARDIAL INFARCTION
The Only AMI Clinical Trials Using Ischemia-Tolerant Mysenchymal Stem Cells (itMSCs) Enter Next Phase Based on Successful Previous Studies
(Source: Feburary 17; Cardio Cell)

CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually. In the United States, CardioCell is initiating a Phase IIa AMI clinical trial to evaluate the clinical safety and efficacy of its itMSCs. In addition, the Ministry of Health in Kazakhstan is beginning a Phase III AMI clinical trial on the intravenous administration of CardioCell’s itMSCs, based on the efficacy and safety found in Phase II clinical trials.

STEMEDICA ANNOUNCES NEW BOARD MEMBER AND CHAIRMAN OF AUDIT COMMITTEE
(Source: February 12 2014; Stemedica Cell Technologies, Inc.)

Stemedica announced today that Richard Mejia, Jr. has joined the Company’s Board of Directors and will be Chairman of the Company’s Audit Committee effective January 31, 2014.

STEMEDICA ANNOUNCES NEW CHIEF FINANCIAL OFFICER
(Source: January 27 2014; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc. a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Craig W. Carlson has been appointed the Company’s Chief Financial Officer effective March, 2014.

STEMEDICA ADVANCES TO PHASE II STROKE TRIAL WITH LEAD PRODUCT STEMEDYNE-MSC
(Source: July 10 2013; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today the completion of enrollment and treatment of patients in a Phase I study with Stemedica’s lead product Stemedyne-MSC. These specially formulated ischemic adult allogeneic mesenchymal stem cells have been manufactured at Stemedica’s cGMP compliant facility and have been successfully used to treat patients in an ischemic stroke study “A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Treatment Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke.”

STEMEDICA ENTERS INTO A GLOBAL DISTRIBUTION AGREEMENT WITH LIFE TECHNOLOGIES
Life Technologies To Distribute Stem Cell Products For Research Use
(Source: June 13 2013; Stemedica Cell Technologies, Inc.)

Stemedica announced today they have entered into a Global Distribution Agreement with Life Technologies Corporation. Under the terms of this agreement, Life Technologies will exclusively offer Stemedica’s ischemic tolerant allogeneic adult mesenchymal stem cells (itMSCs) and neural stem cells (itNSCs) for sale worldwide to research, academic institutions and corporations both in the United States and internationally. Stemedica stem cell lines will be sold under the brand name Gibco® and will be available to purchase for research initiatives beginning Q2, 2013. The label will also carry the name of Stemedica as the manufacturer of the cell lines.

NOTED CARDIOLOGIST ROBERT WILENSKY TO JOIN STEMEDICA CARDIOLOGY DIVISION SCIENTIFIC & MEDICAL ADVISORY BOARD
(Source: May 20 2013; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert L. Wilensky, MD, Professor of Medicine and Director of Interventional Cardiology Research at the University of Pennsylvania has agreed to join the Scientific and Medical Advisory Board for Stemedica’s Cardiology Division.

ROBERT SULLIVAN, PhD, DEAN OF RADY SCHOOL OF MANAGEMENT, TO JOIN STEMEDICA BOARD OF BUSINESS ADVISORS
(Source: May 2 2013; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert Sullivan, PhD, dean of the Rady School of Management at the University of California, San Diego (UC San Diego) has agreed to join the Company’s Business Advisory Board. Dr. Sullivan is an expert on entrepreneurship, knowledge management and operations management.

STEMEDICA ISSUED U.S. PATENT FOR ECTODERMAL STEM CELLS
(Source: April 30; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued “keystone” Patent No. 8,420,394 titled “Culturing Ectodermal Cells Under Reduced Oxygen Tension” by the United States Patent and Trademark Office (USPTO). This patent broadly covers Stemedica’s proprietary manufacturing process for enhancing the proliferation and differentiation potential of ectodermal cells of any origin. The ectodermal layer gives rise to the cells of the skin and nervous system. The patented process provides Stemedica exclusivity for expanding and manufacturing ischemia tolerant ectodermal cells under reduced oxygen tension.

STEMEDICA ENTERS INTO STEM CELL LICENSING AGREEMENT WITH KALBE FARMA COMPANY
Multi-Stem Cell Products Address Disease Conditions in Southeast Asia
(Source: April 25 2013; Stemedica Cell Technologies, Inc.)

Stemedica Asia PTE, LTD, a wholly owned subsidiary of Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced that the Company has entered into a definitive licensing agreement with the Stem Cell and Cancer Institute, a division of PT Kalbe Farma Tbk. (Kalbe). Under the terms of the Agreement Kalbe shall be the exclusive licensor of Stemedica’s ischemic tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical trials in Indonesia, Philippines and Thailand. The Agreement also provides Kalbe with first rights of refusal for additional countries including Singapore, Malaysia, Vietnam, Brunei, Cambodia, Laos and Myanmar. Kalbe’s Stem Cell and Cancer Institute shall be responsible for organizing and funding clinical trials in Southeast Asia.

EMORY CARDIOLOGISTS ARSHED QUYYUMI AND JAVED BUTLER JOIN STEMEDICA CARDIOLOGY DIVISION SCIENTIFIC ADVISORY BOARD
(Source: April 22; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Professors Arshed Quyyumi, MD, FRCP, FACC and Javed Butler, MD, MPH, FACC, FAHA of the Emory Clinical Cardiovascular Research Institute have agreed to join the Scientific Advisory Board for Stemedica’s Cardiology Division.

STEPHEN EPSTEIN, MD TO HEAD SCIENTIFIC & MEDICAL ADVISORY BOARD FOR STEMEDICA’S CARDIOLOGY DIVISION
(Source: March 4; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that cardiologist Stephen E. Epstein, MD, Director of Translational Research of the MedStar Heart Institute, Washington Hospital Center, has accepted the position of Chairman of Stemedica’s Scientific and Medical Advisory Board for the Company’s Cardiology Division. Dr. Epstein served for over 30 years as Chief of the Cardiology Branch of the National Heart, Lung and Blood Institute (NHLBI) in Bethesda, Maryland.

STEMEDICA FORMS CARDIOLOGY DIVISION. SERGEY SIKORA, PhD APPOINTED AS DIVISION PRESIDENT
(Source: February 15; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research, development, and clinical applications announced today that it has formed a Cardiology Division to advance the Company’s national and international clinical trials in chronic heart failure, acute myocardial infarct (AMI) and other cardiac conditions.

STEMEDICA AND THE SCRIPPS RESEARCH INSTITUTE TO JOINTLY INVESTIGATE THE THERAPEUTIC EFFECT OF ISCHEMIA TOLERANT MESENCHYMAL STEM CELLS (itMSC) AND STEM CELL FACTORS IN LUNG INJURY AND SEPSIS
(Source: December 21; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leading manufacturer of adult ischemia tolerant allogeneic stem cells and stem cell factors announced that the Company has signed an agreement with The Scripps Research Institute to investigate the role of Stemedica’s ischemia tolerant human mesenchymal stem cells and stem cell factors as a therapy for severe lung injury and sepsis.

STEMEDICA ISSUED U.S. PATENT FOR STEM CELL TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC OPTIC NEUROPATHY
Multi-Stem Cell Products Address Leading Cause of Adult Blindness
(Source: December 20; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued U.S. Patent #8,318,485 by the United States Patent and Trademark Office. This broad-based patent covers the treatment of diabetic retinopathy and other degenerative diseases of the eye with the Company’s ischemic tolerant neural (itNSC) and mesenchymal (itMSC) stem cells.

NOTED NEUROSURGEON JOSEPH MAROON, MD, FACS TO HEAD STEMEDICA MEDICAL & SCIENTIFIC ADVISORY BOARD
(Source: November 19 2012; Stemedica Cell Technologies, Inc.)

Stemedica announced today that Joseph C. Maroon, MD, FACS Neurosurgeon, Vice Chairman and Professor of the Department of Neurological Surgery at the University of Pittsburgh Medical Center (UPMC) has agreed to serve as Chairman of the Company’s Medical and Scientific Advisory Board. Dr. Maroon is also the Heindl Scholar in Neuroscience at UPMC.

FDA APPROVES STEMEDICA PHASE II CLINICAL TRIAL FOR ACUTE MYOCARDIAL INFARCTION WITH ISCHEMIA TOLERANT MESENCHYMAL STEM CELLS
(Source: October 2 2012; Stemedica Cell Technologies, Inc.)

The U.S. Food and Drug Administration (FDA) has approved its application for an Investigational New Drug (IND) to assess the clinical effects of Stemedyne-MSC (Stemedica’s human bone marrow-derived ischemia tolerant mesenchymal cells) in subjects with a myocardial infarct.

FDA APPROVES STEMEDICA IND APPLICATION FOR STEMEDYNE™-MSC IN CUTANEOUS PHOTOAGING
(Source: September 28; Stemedica Cell Technologies, Inc.)

The U.S. Food and Drug Administration (FDA) has approved its application for an Investigational New Drug (IND) to assess the safety, tolerability and clinical effects of Stemedyne-MSC (Stemedica’s human bone marrow-derived ischemia tolerant mesenchymal cells) in subjects with cutaneous photoaging resulting from overexposure to ultraviolet radiation.

STEMEDICA INTERNATIONAL RECEIVES LICENSES FROM SWISSMEDIC FOR IMPORT AND EXPORT OF ITS STEMEDYNE™ STEM CELL LINE
(Source: August 14 2012; Stemedica International, SA)

Stemedica International, SA (Epalinges, Switzerland), a wholly owned subsidiary of Stemedica Cell Technologies, Inc. (“Stemedica”), a leader in adult stem cell research and manufacturing, announced today that it has been granted a series of licenses by Swissmedic (the Swiss equivalent of the United States Food and Drug Administration). These licenses specifically authorize the Company to import and export its Stemedyne™ stem cell products worldwide for human use in approved clinical trials.

STEMEDICA STEM CELLS APPROVED FOR CLINICAL TRIALS IN MEXICO FOR CHRONIC HEART FAILURE
(Source: May 29 2012; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc. announced today that its strategic partner in Mexico, Grupo Angeles Health Services, has received approval from Mexico’s regulatory agency, COFEPRIS, for a Phase I/II single-blind randomized clinical trial for chronic heart failure. COFEPRIS is the Mexican equivalent of the United States FDA. The clinical trial, to be conducted at multiple hospital sites throughout Mexico, will utilize Stemedica’s adult allogeneic ischemia tolerant mesenchymal stem cells (itMSC) delivered via intravenous infusion. The trial will involve three safety cohorts at different dosages, followed by a larger group being treated with the maximum safe dosage. The COFEPRIS approval is the second approval for the use of Stemedica’s itMSCs. COFEPRIS approved Stemedica’s itMSCs in 2010 for a clinical trial for ischemic stroke. These two trials are the only allogeneic stem cell studies approved by COFEPRIS.

STEMEDICA INTERNATIONAL AND ACADEMIC PARTNER AWARDED SWISS ALZHEIMER’S AND STEM CELL RESEARCH GRANT
(Source: May 24 2012; Stemedica Cell Technologies, Inc.)

Stemedica International, Epalinges, Switzerland, a wholly owned subsidiary of Stemedica Cell Technologies, Inc. (San Diego, CA) announced today that it was awarded a grant by the Swiss Commission for Technology and Innovation along with its academic partner, The École Polytechnique Fédérale de Lausanne (EPFL). The 584,522 CHF (approx. 620,000 USD) grant is focused on the use of EPFL’s advanced imaging capabilities along with Stemedica’s ischemic tolerant stem cells and stem cell factors in transgenic mouse models of Alzheimer’s disease. The basic research supports Stemedica’s clinical trial advancement for Alzheimer’s disease for both Switzerland and the United States.

STEMEDICA ISCHEMIC TOLERANT STEM CELLS PRODUCE SIGNIFICANT IMPROVEMENT IN CARDIAC FUNCTION AFTER HEART ATTACK
(Source: April 3 2012; Stemedica Cell Technologies, Inc.)

Transplanted ischemic tolerant mesenchymal stem cells (itMSC) developed by Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, produced significant improvement in the pumping function of the left ventricle in patients who had experienced a heart attack. The study was presented at the 26th American College of Cardiology (ACC) meeting in Chicago, March 26, 2012 by Daniyar Jumaniyazov, MD, PhD and Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica.

DR. NIKOLAI TANKOVICH, PRESIDENT OF STEMEDICA, APPOINTED LEGATE TO THE CENTER OF SCIENCE AND SOCIETY AT THE UNIVERSITY OF OXFORD
(Source: Mar 15 2012; Stemedica Cell Technologies, Inc.)

The Board of Trusties of the Centre for Science and Society at Trinity College of the University of Oxford, England has appointed Nikolai Tankovich, MD, PhD, FASLMS as a Legate of the Centre. Dr. Tankovich is President and Chief Medical officer of Stemedica Cell Technologies, Inc. and Chairman of Stemedica International S.A.

STEMEDICA GRANTED US PATENT FOR CELLULAR SCAFFOLD
Multi-Stem Cell Products Address Need in the $12.5 Billion Wound Care Field

(Source: February 14 2012; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued U.S. Patent #8,105,380 by the United States Patent and Trademark Office. This broad-based patent covers the combination of scaffolds with stem cells derived from ectodermal and mesenchymal tissue.

STEMEDICA COMPLETES PRE-IND MEETING WITH THE FDA FOR ISCHEMIC TOLERANT NEURAL STEM CELLS (itNSC)
(Source: January 24 2012; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigational New Drug) application to evaluate the safety and efficacy of Stemedica's cGMP manufactured ischemic tolerant allogeneic neural stem cells (adult human) for spinal cord injury.

STEMEDICA NEURAL STEM CELLS SUCCESSFUL IN PRECLINICAL STUDY OF SPINAL CORD INJURY
(Source: November 14 2011; Stemedica Cell Technologies, Inc.)

Transplanted neural stem cells (NSCs) developed by Stemedica were successful in treating rats with spinal cord injury (SCI). The research conducted by Ivan Cheng, M.D., Assistant Professor in the Department of Orthopedic Surgery, Stanford University School of Medicine, was presented at the North American Spine Society Annual Meeting in Chicago, IL on November 2, 2011. Dr. Cheng’s paper was entitled Functional Assessment of Acute Local Versus Distal Transplantation of Human Neural Stem Cells Following Spinal Cord Injury. The data represent a significant finding in the field of spinal cord research.

STEMEDICA COMPLETED ENROLLMENT IN FIRST COHORT OF PATIENTS WITH ISCHEMIC STROKE UTILIZING ALLOGENEIC MESENCHYMAL STEM CELLS
Stroke Study Marks First Use of Unique Stem Cells in Human Trials

(Source: October 21 2011; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that its specially formulated ischemic adult allogeneic mesenchymal stem cells have been successfully used to treat the first cohort of patients in an ischemic stroke study conducted at the University of California, San Diego (UCSD). A total of 35 patients will be enrolled in the clinical trial entitled: “A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke.”

STEMEDICA TREATS FIRST PATIENT WITH ISCHEMIC ALLOGENEIC MESENCHYMAL STEM CELLS
Stroke Study Marks First Use of Unique Stem Cells in Human Trials

(Source: March 24 2011; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that its specially formulated ischemic adult allogeneic mesenchymal stem cells have been successfully used to treat the first patient in an ischemic stroke study conducted at the University of California, San Diego (UCSD). A total of 35 patients will be enrolled in the clinical trial entitled: “A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke.”

STEMEDICA RECEIVES APPROVAL FROM UCSD TO INITIATE ISCHEMIC STROKE STUDY WITH ADULT ALLOGENEIC STEM CELLS
(Source: February 17 2011; Stemedica Cell Technologies, Inc.)

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development announced today that it has received IRB approval from the University of California, San Diego (UCSD) to initiate a Stemedica clinical study entitled, “A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke”. This study will enroll approximately 35 subjects with a clinical diagnosis of ischemic stroke. These patients have significant functional or neurologic impairment that confines them to a wheelchair or requires home nursing care or assistance with the general activities of daily living and have received the ischemic stroke diagnosis at least six months prior to enrollment in this study.

Access prior News Releases by Stemedica:   2010 - 2009 - 2008 - 2007